BCYC vs BDRX

Bicycle Therapeutics plc vs Biodexa Pharmaceuticals plc — Valuation Comparison 2026

BCYC

Biotechnology
Bicycle Therapeutics plc
Quality
6.1
out of 10
Value Trap
24
SAFE
Price
$4.67
Last close
Models
9/13
Active
VS

BDRX

Biotechnology
Biodexa Pharmaceuticals plc
Quality
1.7
out of 10
Value Trap
Price
$3.36
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType BCYC Fair ValueBCYC Upside BDRX Fair ValueBDRX Upside
Bayesian DCF Intrinsic $5.55 +18.7% $0.89 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.45 -67.3% $3.04 -7.9%
Dynamic NAV Asset-Based $9.86 +111.2% $16.83 +413.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BCYC vs BDRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BCYC vs BDRX — Which Stock Is More Undervalued?

BCYC scores higher with a 6.1/10 quality rating vs BDRX's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Bicycle Therapeutics plc (BCYC) and Biodexa Pharmaceuticals plc (BDRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BCYC currently trades at $4.67 with a QOC of 6.1/10, while BDRX trades at $3.36 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).